Photocure: First patient enrolled in Hexvix®/Cysview® Phase 3 Market Expansion Study
Oslo, Norway, October 2, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that the first patient has been enrolled in the Hexvix/Cysview Market Expansion Phase 3 study. The study will investigate the use of Hexvix/Cysview in the outpatient / surveillance setting and is designed to fulfill the FDA post marketing commitments. Results from the Phase 3 study are expected to be available in 2017. The study is a prospective, multicenter Phase 3 study comparing the detection and potential positive